1.
Pediatr Blood Cancer
; 70(4): e30180, 2023 04.
Article
in English
| MEDLINE
| ID: mdl-36720638
ABSTRACT
Acute myeloid leukemia (AML) patients have a wide array of cytogenetic and molecular aberrations, which can influence response to therapy. Monosomy 7 is a rare subset within pediatric AML (prevalence of <2%) that is highly associated with poor outcomes. Fusions involving the anaplastic tyrosine kinase (ALK) gene were exclusively identified in 14.3% of this high-risk cohort, while absent across all other AML. Given the dismal outcomes of monosomy 7, we evaluated the use of crizotinib, an FDA-approved tyrosine kinase inhibitor, used to treat patients with ALK fusions. Our findings suggest that crizotinib may serve as a novel therapy for these patients.
Subject(s)
Leukemia, Myeloid, Acute , Child , Humans , Chromosome Deletion , Crizotinib/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Protein Kinase Inhibitors/therapeutic use , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/therapeutic use
2.
Blood Adv
; 7(9): 1666-1670, 2023 05 09.
Article
in English
| MEDLINE
| ID: mdl-36595452